AR078485A1 - Bifidobacterium longum atcc baa-999 (bl999) y control de peso - Google Patents

Bifidobacterium longum atcc baa-999 (bl999) y control de peso

Info

Publication number
AR078485A1
AR078485A1 ARP100103572A ARP100103572A AR078485A1 AR 078485 A1 AR078485 A1 AR 078485A1 AR P100103572 A ARP100103572 A AR P100103572A AR P100103572 A ARP100103572 A AR P100103572A AR 078485 A1 AR078485 A1 AR 078485A1
Authority
AR
Argentina
Prior art keywords
composition according
composition
atcc baa
weight control
bifidobacterium longum
Prior art date
Application number
ARP100103572A
Other languages
English (en)
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41683555&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078485(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of AR078485A1 publication Critical patent/AR078485A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Uso de Bifidobacterium Iongum ATCC BAA-999 para ayudar al control del peso, promover la perdida de peso y/o para tratar la obesidad. Reivindicacion 2. Composicion de acuerdo con la reivindicacion 1, en donde los humanos o los animales presentan sobrepeso o son obesos. Reivindicacion 3: Composicion de acuerdo con una de las reivindicaciones anteriores, en donde los humanos tienen al menos 16 anos de edad y de preferencia son adultos. Reivindicacion 4: Composicion de acuerdo con una de las reivindicaciones anteriores, en donde la composicion es una composicion farmacéutica, una bebida o un producto alimenticio. Reivindicacion 6: Composicion de acuerdo con la reivindicacion 5, caracterizada porque las bacterias de grado alimentario se seleccionan del grupo que consiste de bacteria de ácido láctico, bifidobacteria, propionibacteria o mezclas de las mismas. Reivindicacion 8: Composicion de acuerdo con la reivindicacion 6 caracterizada porque el prebiotico es seleccionado del grupo que consiste de oligosacáridos y opcionalmente contiene fructosa, galactosa, manosa, soja y/o inulina; fibras dietarias; o mezclas de las mismas. Reivindicacion 9: Composicion de acuerdo con una de las reivindicaciones anteriores, en donde al menos algunas de las Bifidobacterium Iongum ATCC BAA-999 están vivas en la composicion. Reivindicacion 10: Composicion de acuerdo con una de las reivindicaciones anteriores, en donde al menos algunas de las Bifidobacterium Iongum ATCC BAA-999 no están vivas en la composicion.
ARP100103572A 2009-09-30 2010-09-30 Bifidobacterium longum atcc baa-999 (bl999) y control de peso AR078485A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09171866A EP2308499A1 (en) 2009-09-30 2009-09-30 Bifidobacterium longum ATCC BAA-999 (BL999) and weight control

Publications (1)

Publication Number Publication Date
AR078485A1 true AR078485A1 (es) 2011-11-09

Family

ID=41683555

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103572A AR078485A1 (es) 2009-09-30 2010-09-30 Bifidobacterium longum atcc baa-999 (bl999) y control de peso

Country Status (14)

Country Link
US (1) US20120244125A1 (es)
EP (2) EP2308499A1 (es)
JP (1) JP5911424B2 (es)
CN (1) CN102665737A (es)
AR (1) AR078485A1 (es)
AU (1) AU2010303020B2 (es)
BR (1) BR112012007109A2 (es)
CA (1) CA2775976A1 (es)
CL (1) CL2012000809A1 (es)
IN (1) IN2012DN02463A (es)
MX (1) MX2012003612A (es)
RU (1) RU2567660C2 (es)
SG (1) SG10201406169VA (es)
WO (1) WO2011039176A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069553A (zh) * 2016-04-14 2018-12-21 杜邦营养生物科学有限公司 用于增加瘦体重的双歧杆菌

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5615285B2 (ja) * 2010-03-18 2014-10-29 森永乳業株式会社 貧血の予防又は治療用組成物
EP2452575A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Array of age-tailored nutritional formula with probiotics
FI20116008A0 (fi) 2011-10-12 2011-10-12 Maeyrae Maekinen Annika Viskeraalisen rasvan estäminen ja diagnostisointi
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
CN108271917A (zh) 2013-03-08 2018-07-13 艾斯姆食品公司 大米蛋白补充剂
JP6234331B2 (ja) * 2014-06-13 2017-11-22 森永乳業株式会社 統合失調症治療剤
TWI572713B (zh) * 2014-10-31 2017-03-01 豐華生物科技股份有限公司 抗肥胖之乳酸菌菌株及其於食品組成物以及醫藥組成物之應用
JP6650728B2 (ja) * 2015-03-06 2020-02-19 株式会社ファンケル ダイエット用の製剤
CN109069552B (zh) * 2015-12-11 2023-01-24 精密生物集团有限公司 用于治疗肥胖症和相关代谢病的长双歧杆菌
JP6847577B2 (ja) * 2015-12-28 2021-03-24 森永乳業株式会社 ビフィドバクテリウム属細菌および／または乳酸菌の増殖促進および／または減少抑制剤
IT201600105831A1 (it) * 2016-10-20 2018-04-20 Probiotical Spa Una composizione a base di un estratto di Irvingia gabonensis e ceppi di Bifidobatteri per la regolazione e riduzione del peso corporeo
KR101920219B1 (ko) * 2017-03-08 2018-11-20 서울대학교산학협력단 비피더스균을 포함하는 비만 예방 또는 개선용 조성물
WO2018209131A1 (en) 2017-05-12 2018-11-15 Axiom Foods, Inc. Rice products and systems and methods for making thereof
WO2019038449A1 (en) 2017-08-25 2019-02-28 University College Cork - National University Of Ireland, Cork USE OF BIFIDOBACTERIUM LONGUM TO TREAT OBESITY AND PERMIT CONTROL OF WEIGHT
EP3704958A4 (en) * 2017-10-31 2021-06-30 Morinaga Milk Industry Co., Ltd. COMPOSITION FOR INCREASING MUSCLE MASS
US20200345051A1 (en) 2017-11-24 2020-11-05 University College Cork, National University Of Ireland, Cork A composition comprising a cohort of bacteria
CN112672749B (zh) * 2018-04-11 2024-07-23 韩国生命工学研究院 具有肥胖预防或治疗效果的新的长双歧杆菌菌株或鼠李糖乳杆菌菌株及其用途
CN111187734A (zh) * 2019-12-25 2020-05-22 生合生物科技（扬州）有限公司 长双歧杆菌bl986、由其制备的冻干粉及冻干粉的应用
JP7475155B2 (ja) 2020-02-14 2024-04-26 森永乳業株式会社 持久力向上用組成物
EP4070670A1 (en) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61109729A (ja) * 1984-11-05 1986-05-28 Advance Res & Dev Co Ltd コレステロ−ル低下剤
JP2687229B2 (ja) * 1988-11-11 1997-12-08 株式会社ヤクルト本社 血圧降下剤
JP4280016B2 (ja) * 2002-02-28 2009-06-17 雪印乳業株式会社 糖尿病合併症予防・改善・治療剤
JP2003252771A (ja) * 2002-03-04 2003-09-10 Snow Brand Milk Prod Co Ltd 加齢に伴う代謝異常疾患の予防・改善・治療剤
SE529185C2 (sv) * 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
JP2007169200A (ja) * 2005-12-21 2007-07-05 Morinaga Milk Ind Co Ltd インフルエンザ感染予防のための医薬及び飲食品
JP2009524640A (ja) * 2006-01-27 2009-07-02 ダニスコ エー／エス 肥満及びそれに関連する疾患の治療及び予防のためのプロバイオティック微生物の使用
ATE551063T1 (de) * 2006-02-15 2012-04-15 Nestec Sa Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
AU2007242314B2 (en) * 2006-03-31 2010-07-01 Morinaga Milk Industry Co., Ltd. Interleukin production regulator, pharmaceutical composition or food comprising the interleukin production regulator, and method for production of the interleukin production regulator
KR20080075971A (ko) * 2007-02-14 2008-08-20 (주)네오팜 프로바이오틱스 복합 제제
EP1974734A1 (en) 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
EP2022502A1 (en) * 2007-08-10 2009-02-11 Nestec S.A. Lactobacillus rhamnosus and weight control
UA31009U (uk) * 2007-10-18 2008-03-25 Одесская Национальная Академия Пищевых Технологий Кисломолочний напій діабетичного призначення
UA30077U (uk) * 2007-10-18 2008-02-11 Одесская Национальная Академия Пищевых Технологий Композиція для йогурту діабетичного призначення
JP2009143820A (ja) * 2007-12-12 2009-07-02 Tsujido Chemical Corp 高尿酸血症の予防または改善剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069553A (zh) * 2016-04-14 2018-12-21 杜邦营养生物科学有限公司 用于增加瘦体重的双歧杆菌

Also Published As

Publication number Publication date
IN2012DN02463A (es) 2015-05-22
EP2308499A1 (en) 2011-04-13
AU2010303020A1 (en) 2012-04-19
CA2775976A1 (en) 2011-04-07
SG10201406169VA (en) 2014-11-27
US20120244125A1 (en) 2012-09-27
EP2482829A1 (en) 2012-08-08
MX2012003612A (es) 2012-04-19
AU2010303020B2 (en) 2014-11-20
RU2012117804A (ru) 2013-11-20
JP2013506631A (ja) 2013-02-28
CN102665737A (zh) 2012-09-12
JP5911424B2 (ja) 2016-04-27
CL2012000809A1 (es) 2012-07-13
BR112012007109A2 (pt) 2016-07-05
RU2567660C2 (ru) 2015-11-10
WO2011039176A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
AR078485A1 (es) Bifidobacterium longum atcc baa-999 (bl999) y control de peso
AR067906A1 (es) Lactobacillus rhamnosus y control del peso
Sekhon et al. Prebiotics, probiotics and synbiotics: an overview.
AU2010311325B2 (en) Nutritional compositions comprising lactoferrin and probiotics and kits of parts thereof
DK2672980T3 (en) SYNBIOTIC COMPOSITIONS FOR GETTING UP AND RECONSTITUTING GAS MICROFLORA
RU2012111253A (ru) Bifidobacterium longum и функциональные расстройства желудочно-кишечного тракта
AR067971A1 (es) Uso de composicion para la prevencion y/o tratamiento de desordenes metabolicos
AR076862A1 (es) Microorganismos no replicantes y su efecto de refuerzo inmunologico. composicion. metodo para aumentar efectividad de probioticos
Tomar et al. Role of probiotics, prebiotics, synbiotics and postbiotics in inhibition of pathogens
CN113226062A (zh) 包含2’-岩藻糖基乳糖（2’fl）以改善胃肠屏障的营养组合物
BR112016018283A2 (pt) Composição que compreende bifidobacterium animalis ssp. lactis
CL2008000928A1 (es) Uso de bacterias probioticas de las especies lactobacillus rhamnosus, cepas atcc 53103 ó cgmcc 13724 para la fabaricacion de un medicamento o formula infantil que permite reducir el riesgo de que el infante desarrolle obesidad a lo largo de su vida.
MX2009010252A (es) Combinacion simbiotica para mejorar la microbiota intestinal.
BR112013004194A2 (pt) produto simbiótico
BR112019001984A2 (pt) bactérias lácticas e a sua utilização para tratamento prevenção, inibição e/ou redução da formação de biofilmes bacterianos
ATE463558T1 (de) Beta-galactosidase mit transgalactosylierungsaktivität
Peng et al. Polyphenols and tri-terpenoids from Olea europaea L. in alleviation of enteric pathogen infections through limiting bacterial virulence and attenuating inflammation
RU2018139655A (ru) Бифидобактерии для увеличения безжировой массы тела
Erginkaya et al. Potential biotherapeutic properties of lactic acid bacteria in foods
RU2018139656A (ru) Бифидобактерии для снижения потребления пищи, энергии и/или жиров
RU2018145729A (ru) Композиции и способы для маленьких животных из семейства собачьих
Yu et al. Mucin2 is Required for Probiotic Agents-Mediated Blocking Effects on Meningitic E. coli-Induced Pathogenicities S
Ho et al. Effects of supplementation of citrulline and Lactobacillus helveticus ASCC 511 on intestinal epithelial cell integrity
KR20240037256A (ko) 생리학적으로 허용되는 효모 조성물 및 이의 용도
JP2015533484A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure